Repeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxyamethamphetamine

European Journal of Pharmacology

Volumn 546, Issue 1-3, 2006, Pages 74-81

  Callaghan, Paul D ^a,b   Farrand, Kirsten ^a   Salem, Abdallah ^a   Hughes, Patrick ^a   Daws, Lynette C ^a,b   Irvine, Rodney J ^a  

^a Discipline of Pharmacology   (Australia)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

3,4 methylenedioxymethamphetamine; 5 HT; Neurodegeneration; Para methoxyamphetamine; Serotonin transporter

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 METHOXYAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; AMPHETAMINE DERIVATIVE; DOPAMINE; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN HOMOGENATE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ELECTROCHEMICAL DETECTION; ENVIRONMENTAL TEMPERATURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NERVE ENDING; NERVE FIBER DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC TRANSMISSION;

3,4-DIHYDROXYPHENYLACETIC ACID; AMPHETAMINES; ANIMALS; BINDING, COMPETITIVE; BRAIN CHEMISTRY; CEREBRAL CORTEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCHEMISTRY; HALLUCINOGENS; HYDROXYINDOLEACETIC ACID; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PAROXETINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION; TIME FACTORS;

EID: 33748295675     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.07.011     Document Type: Article

References (62)

1. Battaglia G., Yeh S.Y., O'Hearn E., Molliver M.E., Kuhar M.J., and De Souza E.B. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242 (1987) 911-916
2. Battaglia G., Yeh S.Y., and De Souza E.B. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 29 (1988) 269-274
3. Becker J., Neis P., Rohrich J., and Zorntlein S. A fatal paramethoxymethamphetamine intoxication. Leg. Med. (Tokyo) Suppl 1 (2003) S138-S141
4. Bogen I.L., Haug K.H., Myhre O., and Fonnum F. Short- and long-term effects of MDMA ("ecstasy") on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem. Int. 43 (2003) 393-400
5. Byard R.W., Rodgers N.G., James R.A., Kostakis C., and Camilleri A.M. Death and paramethoxyamphetamine - an evolving problem. Med. J. Aust. 176 (2002) 496
6. Callaghan P.D., Irvine R.J., and Daws L.C. Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry. Neurochem. Int. 47 (2005) 350-361
7. Callaghan, P.D., Owens, W.A., Javors, M.A., Sanchez, T.A., Jones, D.J., Irvine, R.J., Daws, L.C., in press. In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long lasting deficits in serotonin transporter function. J. Neurochem.; Manuscript JNC-W-2006-0530.R1.
8. Callahan B.T., Cord B.J., and Ricaurte G.A. Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40 (2001) 113-121
9. Chodorowski Z., Wiergowski M., and Sein Anand J. Fatal intoxication with paramethoxyamphetamine. Przegl. Lek. 59 (2002) 379-380
10. Cimbura G. PMA deaths in Ontario. Can. Med. Assoc. J. 110 (1974) 1263-1267
11. Commins D.L., Vosmer G., Virus R.M., Woolverton W.L., Schuster C.R., and Seiden L.S. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Exp. Ther. 241 (1987) 338-345
12. Dams R., De Letter E.A., Mortier K.A., Cordonnier J.A., Lambert W.E., Piette M.H., Van Calenbergh S., and De Leenheer A.P. Fatality due to combined use of the designer drugs MDMA and PMA: a distribution study. J. Anal. Toxicol. 27 (2003) 318-322
13. Darvesh A.S., Yamamoto B.K., and Gudelsky G.A. Evidence for the involvement of nitric oxide in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in the rat brain. J. Pharmacol. Exp. Ther. 312 (2005) 694-701
14. Daws L.C., Irvine R.J., Callaghan P.D., Toop N.P., White J.M., and Bochner F. Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog. Neuro-psychopharmacol. Biol. Psychiatry 24 (2000) 955-977
15. Farre M., de la Torre R., Mathuna B.O., Roset P.N., Peiro A.M., Torrens M., Ortuno J., Pujadas M., and Cami J. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173 (2004) 364-375
16. Felgate H.E., Felgate P.D., James R.A., Sims D.N., and Vozzo D.C. Recent paramethoxyamphetamine deaths. J. Anal. Toxicol. 22 (1998) 169-172
17. Freezer A., Salem A., and Irvine R.J. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide. Brain Res. 1041 (2005) 48-55
18. Galloway J.H., and Forrest A.R. Caveat emptor: death involving the use of 4-methoxyamphetamine. J. Clin. Forensic Med. 9 (2002) 160
19. Gartside S.E., McQuade R., and Sharp T. Effects of repeated administration of 3,4-methylenedioxymethamphetamine on 5-hydroxytryptamine neuronal activity and release in the rat brain in vivo. J. Pharmacol. Exp. Ther. 279 (1996) 277-283
20. Gough B., Imam S.Z., Blough B., Slikker Jr. W., and Ali S.F. Comparative effects of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: a microdialysis study. Ann. N.Y. Acad. Sci. 965 (2002) 410-420
21. Green A.L., and El Hait M.A. p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. J. Pharm. Pharmacol. 32 (1980) 262-266
22. Green A.R., Cross A.J., and Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology (Berl) 119 (1995) 247-260
23. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55 (2003) 463-508
24. Habert E., Graham D., Tahraoui L., Claustre Y., and Langer S.Z. Characterization of [3H]paroxetine binding to rat cortical membranes. Eur. J. Pharmacol. 118 (1985) 107-114
25. Hewitt K.E., and Green A.R. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats. Neuropharmacology 33 (1994) 1589-1595
26. Huang X., Marona-Lewicka D., and Nichols D.E. p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur. J. Pharmacol. 229 (1992) 31-38
27. Imam, S.Z., Blough, B., Popke, E.J., Slikker Jr., W., Ali, S.F., 2001a. Role of peroxynitrite in paramethoxyamphetamine-induced neurotoxicity. in: Society for Neuroscience, 2001 Abstract Viewer/Itinerary Planner Online., Vol. Program No. 445.21 San Diego, CA.
28. Imam S.Z., Newport G.D., Itzhak Y., Cadet J.L., Islam F., Slikker Jr. W., and Ali S.F. Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J. Neurochem. 76 (2001) 745-749
29. Johansen S.S., Hansen A.C., Muller I.B., Lundemose J.B., and Franzmann M.B. Three fatal cases of PMA and PMMA poisoning in Denmark. J. Anal. Toxicol. 27 (2003) 253-256
30. Johnson M.P., and Nichols D.E. Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats. Neuropharmacology 30 (1991) 819-822
31. Kaminskas L.M., Irvine R.J., Callaghan P.D., White J.M., and Kirkbride P. The contribution of the metabolite p-hydroxyamphetamine to the central actions of p-methoxyamphetamine. Psychopharmacology (Berl) 160 (2002) 155-160
32. Kitchen I., Tremblay J., Andre J., Dring L.G., Idle J.R., Smith R.L., and Williams R.T. Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 9 (1979) 397-404
33. Kraner J.C., McCoy D.J., Evans M.A., Evans L.E., and Sweeney B.J. Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). J. Anal. Toxicol. 25 (2001) 645-648
34. Lew R., Sabol K.E., Chou C., Vosmer G.L., Richards J., and Seiden L.S. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. J. Pharmacol. Exp. Ther. 276 (1996) 855-865
35. Lim H.K., and Foltz R.L. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem. Res. Toxicol. 1 (1988) 370-378
36. Lora-Tamayo C., Tena T., Rodriguez A., Moreno D., Sancho J.R., Ensenat P., and Muela F. The designer drug situation in Ibiza. Forensic Sci. Int. 140 (2004) 195-206
37. Malberg J.E., and Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J. Neurosci. 18 (1998) 5086-5094
38. McCann U.D., Ridenour A., Shaham Y., and Ricaurte G.A. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 10 (1994) 129-138
39. McCann U.D., Mertl M., Eligulashvili V., and Ricaurte G.A. Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology (Berl) 143 (1999) 417-425
40. McKenna D.J., and Peroutka S.J. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J. Neurochem. 54 (1990) 14-22
41. Menon M.K., Tseng L.F., and Loh H.H. Pharmacological evidence for the central serotonergic effects of monomethoxyamphetamines. J. Pharmacol. Exp. Ther. 197 (1976) 272-279
42. Morgan M.J. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 152 (2000) 230-248
43. Nichols D.E., Ilhan M., and Long J.P. Comparison of cardiovascular, hyperthermic, and toxic effects of para-methoxyamphetamine (PMA) and 3, 4-methylenedioxyamphetamine (MDA). Arch. Int. Pharmacodyn. Ther. 214 (1975) 133-140
44. Nichols D.E., Brewster W.K., Johnson M.P., Oberlender R., and Riggs R.M. Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). J. Med. Chem. 33 (1990) 703-710
45. O'Hearn E., Battaglia G., De Souza E.B., Kuhar M.J., and Molliver M.E. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J. Neurosci. 8 (1988) 2788-2803
46. O'Shea E., Granados R., Esteban B., Colado M.I., and Green A.R. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37 (1998) 919-926
47. Parrott A.C. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum. Psychopharmacol. 16 (2001) 557-577
48. Pubill D., Canudas A.M., Pallas M., Camins A., Camarasa J., and Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn-Schmiedeberg's Arch. Pharmacol. 367 (2003) 490-499
49. Raiteri M., del Carmine R., and Bertollini A. Effect of desmethylimipramine on the release of (3H)norepinephrine induced by various agents in hypothalamic synaptosomes. Mol. Pharmacol. 13 4 (1977) 746-758
50. Refstad S. Paramethoxyamphetamine (PMA) poisoning; a 'party drug' with lethal effects. Acta Anaesthesiol. Scand. 47 (2003) 1298-1299
51. Sabol K.E., Lew R., Richards J.B., Vosmer G.L., and Seiden L.S. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. J. Pharmacol. Exp. Ther. 276 (1996) 846-854
52. Scanzello C.R., Hatzidimitriou G., Martello A.L., Katz J.L., and Ricaurte G.A. Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J. Pharmacol. Exp. Ther. 264 (1993) 1484-1491
53. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240 (1987) 1-7
54. Series H.G., Cowen P.J., and Sharp T. p-Chloroamphetamine (PCA), 3,4-methylenedioxy-methamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo. Psychopharmacology (Berl) 116 (1994) 508-514
55. Shankaran M., and Gudelsky G.A. A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology (Berl) 147 (1999) 66-72
56. Sprague J.E., Johnson M.P., Schmidt C.J., and Nichols D.E. Studies on the mechanism of p-chloroamphetamine neurotoxicity. Biochem. Pharmacol. 52 (1996) 1271-1277
57. Steele T.D., Katz J.L., and Ricaurte G.A. Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA). Brain Res. 589 (1992) 349-352
58. Vollenweider F.X., Liechti M.E., Gamma A., Greer G., and Geyer M. Acute psychological and neurophysiological effects of MDMA in humans. J. Psychoact. Drugs 34 (2002) 171-184
59. Voorspoels S., Coucke V., Covaci A., Maervoet J., Schepens P., De Meyere C., and Jacobs W. Resurgence of a lethal drug: paramethoxyamphetamine deaths in Belgium. J. Toxicol., Clin. Toxicol. 40 (2002) 203-204
60. Wang X., Baumann M.H., Xu H., and Rothman R.B. 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 53 (2004) 240-248
61. Wang X., Baumann M.H., Xu H., Morales M., and Rothman R.B. ({+/-})-3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. J. Pharmacol. Exp. Ther. 314 (2005) 1002-1012
62. White J.M., Bochner F., and Irvine R.J. The agony of "ecstasy". Med. J. Aust. 166 (1997) 117-118